Alzamend Neuro (ALZN) Institutional Ownership $1.01 -0.01 (-0.98%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.02 +0.01 (+0.99%) As of 03/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Alzamend Neuro (NASDAQ:ALZN)CurrentInstitutional OwnershipPercentage49.61%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$339.27KNumber ofInstitutional Sellers(last 12 months)0 Get ALZN Insider Trade Alerts Want to know when executives and insiders are buying or selling Alzamend Neuro stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ALZN Institutional Buying and Selling by Quarter Remove Ads Alzamend Neuro Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Citadel Advisors LLC30,638$36K0.0%N/A0.564% 2/12/2025 Geode Capital Management LLC33,540$39K0.0%N/A0.618% 5/20/2024 Virtu Financial LLC26,482$26K0.0%N/A0.385% 2/2/2024 Truist Financial Corp154,327$137K0.0%-93.3%2.168% 5/11/2022 RFG Advisory LLC250,000$308K0.0%N/A0.277% 5/9/2022 Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087% 4/22/2022 Truist Financial Corp2,314,907$2.85M0.0%N/A2.569% 1/31/2022 Commonwealth Equity Services LLC116,666$221K0.0%N/A0.131% 11/16/2021 Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036% 11/16/2021 Two Sigma Investments LP172,913$533K0.0%N/A0.199% 11/16/2021 Warberg Asset Management LLC14,000$43K0.0%N/A0.016% 11/15/2021 Sassicaia Capital Advisers LLC93,762$289K0.8%N/A0.108% 9/17/2021 Virtu Financial LLC15,402$135K0.0%N/A0.018% 8/16/2021 Cubist Systematic Strategies LLC23,672$207K0.0%N/A0.028% 8/13/2021 Geode Capital Management LLC44,600$389K0.0%N/A0.052% 8/11/2021 Susquehanna International Group LLP57,030$498K0.0%N/A0.067% (Data available from 1/1/2016 forward)Remove Ads ALZN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALZN shares? During the previous two years, the following institutional investors and hedge funds held shares of Alzamend Neuro shares: Truist Financial Corp ($137K), Geode Capital Management LLC ($39K), and Citadel Advisors LLC ($36K), Virtu Financial LLC ($26K).Learn more on ALZN's institutional investors. What percentage of Alzamend Neuro stock is owned by institutional investors? 49.61% of Alzamend Neuro stock is owned by institutional investors. Learn more on ALZN's institutional investor holdings. Which institutional investors have been buying Alzamend Neuro stock? The following institutional investors have purchased Alzamend Neuro stock in the last 24 months: Geode Capital Management LLC ($33.54K), Citadel Advisors LLC ($30.64K), and Virtu Financial LLC ($26.48K). How much institutional buying is happening at Alzamend Neuro? Institutional investors have bought a total of 90,660 shares in the last 24 months. This purchase volume represents approximately $339.27K in transactions. Which Alzamend Neuro major shareholders have been selling company stock? The following institutional investors have sold Alzamend Neuro stock in the last 24 months: Truist Financial Corp ($2.16M). How much institutional selling is happening at Alzamend Neuro? Institutional investors have sold a total of 2,160,580 shares in the last 24 months. This volume of shares sold represents approximately $19.23M in transactions. Related Companies Cara Therapeutics Institutional Ownership Calidi Biotherapeutics Institutional Ownership Allakos Institutional Ownership Finch Therapeutics Group Institutional Ownership CEL-SCI Institutional Ownership Cyclo Therapeutics Institutional Ownership Chemomab Therapeutics Institutional Ownership Natural Alternatives International Institutional Ownership Lisata Therapeutics Institutional Ownership NanoViricides Institutional Ownership This page (NASDAQ:ALZN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
